If you have atrial fibrillation (AFib), your doctor may discuss a WATCHMAN device as one option for reducing stroke risk. The device is designed to close the left atrial appendage (LAA), a small pouch in the upper left chamber of the heart where blood can collect and form clots in some people with AFib.
The WATCHMAN device is not a treatment that cures atrial fibrillation itself. Instead, it is a form of left atrial appendage closure (LAAC) intended to reduce the risk of blood clots leaving the heart and causing a stroke. The U.S. Food and Drug Administration (FDA) has approved WATCHMAN FLX and WATCHMAN FLX Pro for specific patients with non-valvular atrial fibrillation who meet defined stroke-risk and treatment criteria.
This guide explains what the WATCHMAN device is, who may be considered for it, how the procedure works, possible benefits and risks, recovery, and how it compares with anticoagulant treatment.
What Is the WATCHMAN Device?
The WATCHMAN device is a small implant used to close the opening of the left atrial appendage. It is delivered through a catheter rather than through open-heart surgery.
The underlying idea is relatively straightforward. In people with non-valvular AFib, blood can become stagnant in the left atrial appendage. A clot that forms there can potentially travel through the bloodstream and cause an ischemic stroke. Closing the appendage can reduce the pathway through which those clots can enter circulation.
The WATCHMAN FLX and WATCHMAN FLX Pro are FDA-approved left atrial appendage closure devices. The FDA’s current labeling includes patients with non-valvular atrial fibrillation who have an increased risk of stroke and systemic embolism, are recommended for anticoagulation, are considered suitable for anticoagulation, and have an appropriate reason to seek a non-pharmacologic alternative after considering the safety and effectiveness of the device compared with anticoagulation.
Primary entity map: WATCHMAN device → left atrial appendage → atrial fibrillation → blood clot → thromboembolism → ischemic stroke → anticoagulation → left atrial appendage closure.
Why Is the Left Atrial Appendage Important?
The left atrial appendage is a small pouch attached to the left atrium. In people with AFib, the irregular heart rhythm can contribute to blood pooling in the appendage. When blood remains relatively still, a clot can develop.
If a clot leaves the appendage and enters the bloodstream, it can travel to the brain and contribute to an ischemic stroke. This is why stroke prevention is an important part of atrial fibrillation management.
The American Heart Association explains that left atrial appendage occlusion blocks or closes the opening of the appendage. Several techniques can be used, including catheter-delivered devices.
It is important to understand that closing the appendage does not correct the abnormal electrical rhythm responsible for AFib. Treatment of the rhythm and treatment of stroke risk are separate parts of AFib care.
Who May Be Considered for a WATCHMAN Device?
A WATCHMAN implant is not appropriate for everyone with AFib.
Eligibility depends on several factors, including:
- Whether the patient has non-valvular atrial fibrillation
- The person’s estimated risk of stroke or systemic embolism
- Whether anticoagulant therapy is recommended
- Whether the patient is considered suitable for anticoagulation
- The patient’s reason for considering a non-drug alternative
- Heart anatomy and the size and shape of the left atrial appendage
- Overall health and procedural risk
- The treating team’s assessment of expected benefits and risks
The FDA’s current labeling specifies these criteria for WATCHMAN FLX and WATCHMAN FLX Pro.
Clinical guidelines also recognize percutaneous left atrial appendage occlusion as an option for selected patients. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline states that percutaneous LAA occlusion is reasonable in patients with a sufficiently high stroke risk and a contraindication to long-term oral anticoagulation. It may also be reasonable for some patients with moderate to high stroke risk and a high risk of major bleeding while taking anticoagulation.
That means the decision is individualized rather than based on AFib alone.
How Does the WATCHMAN Procedure Work?
The WATCHMAN procedure is performed through a catheter-based approach.
1. Preparation
Before implantation, the medical team evaluates the patient’s medical history, stroke risk, bleeding risk, heart anatomy, and suitability for the procedure.
Cardiac imaging is used to examine the left atrial appendage and help determine whether the anatomy is suitable for device placement.
2. Catheter Access
The physician typically accesses a blood vessel, commonly through the groin, and guides a catheter toward the heart.
The procedure involves crossing from the right side of the heart to the left atrium through the atrial septum, a technique known as transseptal access.
3. Device Placement
The WATCHMAN device is delivered through the catheter and positioned at the opening of the left atrial appendage.
Once the physician confirms appropriate positioning, the device is released.
4. Closure of the Appendage
The device sits at the entrance of the appendage and acts as a barrier. Over time, heart tissue grows over the implant, helping seal the opening.
5. Follow-Up
Follow-up imaging and medication management are important after implantation. The exact medication regimen depends on the device, clinical circumstances, and the treating physician’s instructions.
The FDA approved an updated labeling pathway in July 2025 that expanded indications to include certain patients following catheter ablation for non-valvular AFib and added a post-implant drug regimen to the labeling.
What Are the Potential Benefits?
For appropriately selected patients, left atrial appendage closure can provide a non-pharmacologic approach to reducing thromboembolic risk associated with the left atrial appendage.
Potential advantages may include:
Reducing Dependence on Long-Term Anticoagulation
Some patients seek an alternative to ongoing blood-thinning medication because of bleeding concerns, difficulty maintaining treatment, or other medical considerations.
However, a WATCHMAN implant does not automatically mean that a person can immediately stop all anticoagulant or antiplatelet medications. Medication requirements after implantation vary and must be determined by the treating medical team.
Targeting the Main Source of Clot Formation
The procedure directly addresses the left atrial appendage, where clots commonly develop in people with non-valvular AFib.
Avoiding Open-Heart Surgery
The device is implanted using a catheter-based procedure rather than conventional open-heart surgery.
Long-Term Stroke Prevention Strategy
For appropriate patients, LAA closure can become part of a long-term strategy for reducing stroke risk associated with AFib.
The ACC/AHA guideline supports LAA occlusion for selected patients based on stroke risk, bleeding risk, and suitability for oral anticoagulation.
WATCHMAN Device vs. Blood Thinners
One of the most common questions is whether the WATCHMAN device is better than anticoagulants.
There is no universal answer.
Anticoagulants, including direct oral anticoagulants and warfarin, remain important treatments for stroke prevention in many people with AFib. The choice between medication and LAA closure depends on the individual’s stroke risk, bleeding risk, medical history, anatomy, preferences, and clinical circumstances.
The 2023 ACC/AHA/ACCP/HRS guideline continues to recommend anticoagulation for appropriate patients while recognizing percutaneous LAA occlusion as an option for selected individuals.
A useful way to think about the distinction is:
| Approach | Main purpose | Key consideration |
|---|---|---|
| Anticoagulant medication | Reduces clotting throughout the circulation | Requires ongoing medication and monitoring appropriate to the drug |
| WATCHMAN device | Closes the left atrial appendage | Requires an invasive catheter procedure and follow-up |
| AFib ablation | Treats abnormal electrical pathways causing AFib | Does not by itself eliminate the need for stroke-risk management |
The appropriate strategy should be determined through shared decision-making with a qualified cardiovascular specialist.
What Are the Risks of the WATCHMAN Procedure?
Like any invasive heart procedure, WATCHMAN implantation has potential risks.
Possible complications include:
- Bleeding
- Pericardial effusion or cardiac tamponade
- Vascular complications
- Device embolization
- Device-related thrombosis
- Stroke or systemic embolism
- Infection
- Anesthesia-related complications
- Damage to nearby cardiac structures
The exact risk depends on patient characteristics, anatomy, medical history, and procedural factors.
The FDA continues to update WATCHMAN labeling and safety information. For example, an FDA supplement approved in November 2025 added warnings and instructions intended to reduce the risk of air embolism during use.
Because the procedure has meaningful potential complications, it should be performed by appropriately trained specialists. The SCAI/HRS expert consensus statement emphasizes operator experience and patient-provider shared decision-making for transcatheter left atrial appendage closure.
What Is Recovery Like After WATCHMAN Implantation?
Recovery varies from patient to patient.
Because WATCHMAN is implanted through a catheter rather than open-heart surgery, recovery is generally different from recovery after major open-heart procedures.
Your medical team may provide instructions about:
- Activity restrictions
- Incision or access-site care
- Medication use
- Follow-up appointments
- Warning signs that require urgent attention
- Follow-up imaging
Follow-up is particularly important because the medical team needs to assess the device and the left atrial appendage after implantation.
Patients should not stop prescribed anticoagulants or antiplatelet medications on their own. The post-procedure medication plan is individualized.
Does the WATCHMAN Device Cure Atrial Fibrillation?
The WATCHMAN device is intended to reduce thromboembolic risk associated with the left atrial appendage. It does not correct the abnormal electrical activity that causes atrial fibrillation.
AFib treatment may involve medications, cardioversion, catheter ablation, lifestyle and risk-factor management, or other approaches depending on the individual.
This distinction matters because a person can still have AFib after receiving a WATCHMAN implant.
WATCHMAN and Catheter Ablation
WATCHMAN and catheter ablation address different aspects of AFib management.
Catheter ablation aims to treat abnormal electrical signals that contribute to AFib.
WATCHMAN implantation closes the left atrial appendage to reduce thromboembolic risk.
The FDA expanded WATCHMAN FLX and WATCHMAN FLX Pro labeling in 2025 to include certain patients following catheter ablation for non-valvular AFib.
Whether both procedures are appropriate depends on the patient’s individual clinical situation.
Questions to Ask Your Cardiologist
If your doctor has mentioned a WATCHMAN device, consider asking:
- What is my estimated stroke risk?
- Why might left atrial appendage closure be appropriate for me?
- Am I a suitable candidate for WATCHMAN?
- What are my alternatives to the procedure?
- How does my bleeding risk affect the decision?
- What medications will I need after implantation?
- What follow-up imaging will I need?
- What complications should I watch for?
- How experienced is the medical team with LAAC procedures?
- Will I still need treatment for atrial fibrillation after implantation?
These questions can help you understand the trade-offs before making a treatment decision.
